MedPath

Is there a role of Gabapentin as Add-on therapy in Dystonic Cerebral Palsy?

Phase 3
Conditions
Health Condition 1: G808- Other cerebral palsy
Registration Number
CTRI/2018/12/016689
Lead Sponsor
Jaslok Hospital and Research Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1) Diagnosed case of dystonic cerebral palsy

2) Participants on stable medication for tone for last 4 weeks

3) Participants on stable rehabilitation programme for last 6 weeks

4) Participants are able to swallow the drug

5) Parents/ caregivers are able to understand/comply with the study trial requirements

Exclusion Criteria

1) Known allergy to Gabapentin and/or its ingredients

2) Age less than 2 years and greater than 18 years at the enrollment

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Barry Albright Dystonia Scale <br/ ><br>Movement Disorder- Childhood Rating ScaleTimepoint: 0, 12 and 24 weeks
Secondary Outcome Measures
NameTimeMethod
Monitoring side effectsTimepoint: 4 weeks, 12 weeks and 24 weeks;PEDsQLTimepoint: Day 0, 12 weeks and 24 weeks
© Copyright 2025. All Rights Reserved by MedPath